Placebo News and Research

RSS

Genticel completes patient enrollment for ProCervix phase II study

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, today announces the completion of patient enrollment of the phase II study of its lead therapeutic vaccine candidate, ProCervix.

14 Nov 2014

Rare gene mutation linked to lower cholesterol levels, reduced risk of heart attack

Rare mutations that shut down a single gene are linked to lower cholesterol levels and a 50 percent reduction in the risk of heart attack, according to new research from Washington University School of Medicine in St. Louis, the Broad Institute at Massachusetts Institute of Technology and Harvard, and other institutions.

14 Nov 2014

Vitamin B12, folic acid supplements may not reduce risk of memory and thinking problems

Taking vitamin B12 and folic acid supplements may not reduce the risk of memory and thinking problems after all, according to a new study published in the November 12, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology. The study is one of the largest to date to test long-term use of supplements and thinking and memory skills.

13 Nov 2014

Schizophrenia symptom severity predicts atypical antipsychotic benefit

Atypical antipsychotic drugs benefit patients with acute schizophrenia across the full spectrum of symptom severity, as well as highly symptomatic patients with predominantly negative symptoms, suggests a meta-analysis published in JAMA Psychiatry.

12 Nov 2014

HLD-200 successfully meets primary endpoint in Phase III study

Highland Therapeutics Inc., a pharmaceutical company, today announced that its wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. has reported positive top-line results from its recently completed Phase III study.

11 Nov 2014

FDA accepts Amgen's evolocumab BLA for review

Amgen today announced that the U.S. Food and Drug Administration has accepted for review Amgen's Biologics License Application (BLA) for evolocumab for the treatment of high cholesterol.

11 Nov 2014

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in patients with asthma

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.

11 Nov 2014

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014.

10 Nov 2014

Cardiome Pharma announces results from Phase 3 clinical study of BRINAVESS

Cardiome Pharma Corp. today announced results from a Phase 3 clinical study conducted with BRINAVESS (vernakalant intravenous, RSD 1235) in the Asia-Pacific (A-P) region.

7 Nov 2014

Obeticholic acid improves liver health in people with nonalcoholic steatohepatitis

An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the National Institutes of Health. The FLINT study found that people with nonalcoholic steatohepatitis (NASH) who took obeticholic acid (OCA) had improved liver health during that period, including decreased inflammation and fat in the liver and decreased body weight versus people receiving a placebo. OCA was also associated with increases in itching and total cholesterol.

7 Nov 2014

New AGA guidelines provide guidance on IBS treatments

Up to 15 percent of the general adult population is affected by irritable bowel syndrome (IBS), and most patients struggle to find effective drug therapy. A new guideline from the American Gastroenterological Association provides these patients and their physician's guidance.

6 Nov 2014

NIH boosts funding for first large-scale clinical trial aimed at identifying drugs for Alzheimer's

The National Institutes of Health has boosted funding for the first large-scale clinical trial aimed at identifying drugs to stop or slow Alzheimer's disease in people destined to get the debilitating illness.

6 Nov 2014

Dual intragastric balloon procedure shows promise for people with obesity

After six months, people with intragastric balloons in their stomachs lost more than twice their excess weight, compared to people who tried to lose weight under a medically supervised diet and exercise program alone, according to new research from a randomized clinical trial presented here at ObesityWeek 2014, the largest international event focused on the basic science, clinical application and prevention and treatment of obesity.

6 Nov 2014

New study finds link between conflict and reinforcement learning

We celebrate our triumphs over adversity, but let's face it: We'd rather not experience difficulty at all. A new study ties that behavioral inclination to learning: When researchers added a bit of conflict to make a learning task more difficult, that additional conflict biased learning by reducing the influence of reward and increasing the influence of aversion to punishment.

6 Nov 2014

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.

5 Nov 2014

Hospira launches Paricalcitol Injection

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced the launch of Paricalcitol Injection, a generic version of AbbVie's Zemplar. Hospira obtained U.S. Food and Drug Administration approval of paricalcitol on Oct. 21 and launched the product Nov. 1.

5 Nov 2014

New studies offer hope for breast cancer survivors struggling with cancer-related pain, swelling

Two new studies from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania offer hope for breast cancer survivors struggling with cancer-related pain and swelling, and point to ways to enhance muscular strength and body image.

5 Nov 2014

Placebo News and Research

Genticel completes patient enrollment for ProCervix phase II study

Rare gene mutation linked to lower cholesterol levels, reduced risk of heart attack

Vitamin B12, folic acid supplements may not reduce risk of memory and thinking problems

Schizophrenia symptom severity predicts atypical antipsychotic benefit

HLD-200 successfully meets primary endpoint in Phase III study

FDA accepts Amgen's evolocumab BLA for review

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in patients with asthma

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Cardiome Pharma announces results from Phase 3 clinical study of BRINAVESS

Obeticholic acid improves liver health in people with nonalcoholic steatohepatitis

New AGA guidelines provide guidance on IBS treatments

NIH boosts funding for first large-scale clinical trial aimed at identifying drugs for Alzheimer's

Dual intragastric balloon procedure shows promise for people with obesity

New study finds link between conflict and reinforcement learning

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Hospira launches Paricalcitol Injection

New studies offer hope for breast cancer survivors struggling with cancer-related pain, swelling

Common drug could become the future standard of care for HE patients

Gefitinib drug boosts oesophageal cancer patients' survival by up to six months

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News